CHOSA participated in the contest organized by the Jiangning and Nanjing National Economic Development Zone authorities, where the company received recognition for its innovative work. CHOSA's Chief Commercial Officer, Claus Frisenberg Pedersen, represented the company and acknowledged the professional engagement of local and regional officials.

Building on this success, CHOSA plans to explore concrete collaboration opportunities with research institutions, biotech companies, and investors in Nanjing and the greater Shanghai region.

China is at the forefront of developing next-generation immunotherapies, where synergy with platinum-based chemotherapy remains critical. The CHOSA Platin-DRP® offers a predictive technology that can provide valuable differentiation in this highly competitive space. With more than half of all new immunotherapy drugs (mostly PD-1 /PD-L1 inhibitors) now developed in China -and most have demonstrated synergy in combination with platin chemotherapy- the CHOSA platform represents a strategic and commercially highly relevant innovation.

The Nanjing region stands out as an attractive hub for such collaborations, combining a strong innovation ecosystem, world-class research capabilities, and a highly supportive business environment within the greater Shanghai area.

For additional information, contact
Peter Buhl Jensen, CEO  Claus Frisenberg Pedersen, CCO
Peter@chosa.bio   Claus@chosa.bio  
+ 45 21 60 89 22   +45 61 61 66 41

Background

Cisplatin and its sister compound carboplatin are mainstays of lung cancer therapy. Even with advances in immunotherapy, platinum drugs remain essential components of treatment regimens, including combinations with PD-1/L1 inhibitors as Keytruda and Opdivo and newer dual-binder immunotherapies. Surprising synergy between platin and PD-1/PD-L1 products have been shown repeatedly, and they are now the mainstay in lung cancer treatment. While having revolutionized lung cancer therapy, only 50% benefit from these new platinum combination therapies. Numerous studies have been focused on predicting the effect of immunotherapy with limited success. While many attempts to predict cisplatin efficacy have failed, the Platin-DRP®-a 205-gene biomarker signature-has demonstrated promising results in other settings, including improved outcomes in adjuvant NSCLC therapy and progression-free survival in breast cancer.

This study explored the predictive potential of the Platin-DRP® not only in cisplatin-treated patients but also in those treated with carboplatin. The SPLENDOUR trial provided a unique opportunity to validate this tool in a well-characterized cohort, potentially confirming its clinical utility across both platinum drugs. Future research will investigate whether the Platin-DRP® can also predict benefit from platinum-PD-1/L1 inhibitor combinations.

CHOSA in short
CHOSA Oncology AB is a precision oncology biotechnology company developing Drug Response Predictor (DRP®) tests to personalize chemotherapy and improve patient outcomes. By matching the right patient with the right drug, CHOSA aims to extend survival and reduce unnecessary toxicity across multiple cancer types.

The company is led by an experienced international team of specialists in oncology, drug development, clinical trials, regulatory strategy, and business development.

About Platin-DRP® also referred to as LiPlaCis DRP®, a 205 gene test to predict if platin treatment is likely to be successful

CHOSA is focused on late-stage clinical development of LiPlaCis® and its DRP® drug response predictor to which it has worldwide rights. The Platin-DRP is the only proven test to foresee and thereby select who to treat and who will benefit from cisplatin and carboplatin. Breast: We have strong phase 2b data in metastatic breast cancer, demonstrating that patients selected by Platin-DRP® responded better to treatment; have longer progression-free survival; and maybe even an overall longer total survival than those patients who were identified as unlikely to respond well to the treatment. In addition, CHOSA will in October 2025 present new carboplatin breast cancer data at ESMO in Berlin.

Lung: The Platin-DRP has now shown its ability in three studies of lung cancer to foresee the value of platin therapy in lung cancer. Cisplatin / carboplatin therapy is a gold standard that increases lung cancer cure, but not always, and until now the doctors do not know who will benefit from cisplatin or carboplatin and who should have something else. This is where the Platin-DRP® is a potential game changer, especially in new neoadjuvant treatment where immunotherapy obtains high efficacy rates when combined with platin doublets.

Immunotherapy There is a new development that adds further value to our DRP. Cisplatin has often been shown to activate the immune system (making cold tumors hot), which makes tumors susceptible to PD1 inhibitors. This synergy is particularly important but not limited to the treatment of lung cancer, bladder cancer, and head and neck cancer. In the ever-growing PD1 inhibitor market, where competition is fierce, our company stands out with the ability to predict if cisplatin will provide synergy with PD1. This can give the PD1 selling companies a significant competitive advantage.

DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA. LiPlaCis is in-licensed from Allarity Therapeutics, Inc., (previous Oncology Venture ApS) and LiPlasome Pharma ApS.